The pandemic of coronavirus disease (COVID)-2019 has been affected many people all around the world. Patients with mental disorders are not as safe as others; also, they might be more vulnerable in such situations. These patients take various medications, which can lead to numerous drug-drug interactions with experimental drugs uses against COVID-19. According to the potential critical interactions, we reviewed the reputable databases to find the interactions between main categories of psychiatric medications (e.g., antidepressants, anti-psychotics, sedative/hypnotics, and mood stabilizers) when used in concomitant with COVID-19 experimental agents (e.g., hydroxychloroquine, lopinavir/ritonavir, atazanavir, and chloroquine). We hope the list provided in this review helps the clinical care staff in treating patients with mental illness infected with severe acute respiratory syndrome coronavirus 2 during the COVID-19 pandemic.
CITATION STYLE
Baradaran, H., Gorgzadeh, N., Seraj, H., Asadi, A., Shamshirian, D., & Rezapour, M. (2020, January 2). Drug-drug interaction between psychiatric medications and experimental treatments forcoronavirusdisease-19:A mini-review. Open Access Macedonian Journal of Medical Sciences. Scientific Foundation SPIROSKI. https://doi.org/10.3889/oamjms.2020.5010
Mendeley helps you to discover research relevant for your work.